To read the full article sign up for free or sign in.

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

March 4, 2025

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug technology and assets in-licensed from Hummingbird Bioscience Pte Ltd.

BioWorld BioWorld Asia Financings Newco news Cancer Immune Inflammatory Antibody-drug conjugate Monoclonal antibody Series A Asia-Pacific U.S.

Today's news in brief

BioWorld

BioWorld briefs for March 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 18, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...